Loading…

Roles of PD‐L1 in human adipose‐derived mesenchymal stem cells under inflammatory microenvironment

Mesenchymal stem cells (MSCs) display unique homing and immunosuppression features which make them promising candidates for cell therapy in inflammatory disorders. It is known that C‐X‐C chemokine receptor type 4 (CXCR4, also known as CD184) is a critical receptor implicated in MSCs migration, and t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular biochemistry 2024-04, Vol.125 (4), p.e30544-n/a
Main Authors: Sun, Jinqiu, Zhong, Hannah, Kang, Bo, Lum, Trenton, Liu, Dongxue, Liang, Shengxian, Hao, Jijun, Guo, Rui
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mesenchymal stem cells (MSCs) display unique homing and immunosuppression features which make them promising candidates for cell therapy in inflammatory disorders. It is known that C‐X‐C chemokine receptor type 4 (CXCR4, also known as CD184) is a critical receptor implicated in MSCs migration, and the protein programmed death ligand‐1 (PD‐L1) is involved in MSC's immunosuppression. However, it remains unclear how the molecular mechanisms regulate PD‐L1 expression for migration and immunosuppression of MSCs under the inflammatory microenvironment. In this article, we used the human adipose‐derived mesenchymal stem cells (hADMSCs) treated with lipopolysaccharide (LPS) as an in vitro inflammatory model to explore the roles of PD‐L1 on the migration and immunosuppression of MSC. Our results demonstrate that in hADMSCs, LPS significantly increased PD‐L1 expression, which mediated the migration of the LPS‐treated hADMSCs via CXCR4. In addition, we found that the increased PD‐L1 expression in the LPS‐treated hADMSCs inhibited B cell proliferation and immunoglobulin G secretion through nuclear factor‐κB. Our study suggests that the PD‐L1 plays critical roles in the homing and immunosuppression of MSCs which are a promising cell therapy to treat inflammatory diseases.
ISSN:0730-2312
1097-4644
1097-4644
DOI:10.1002/jcb.30544